Glioblastoma and ascorbate
A diagnosis of the brain cancer glioblastoma is devastating, and despite modern treatment, median survival with this cancer is only 15 months. New treatment options are desperately needed. Improved understanding of the biology of glioblastoma has highlighted conditions, such as low oxygen availability in the tumour (hypoxia) and epigenetic modifications to DNA, that enhance cancer growth and resistance to therapy.
Recent information from other cancers indicates that these conditions can be modified by increased levels of vitamin C (ascorbate). In this project, we propose to analyse glioblastoma tumours from the Christchurch Cancer Society Tissue Bank to investigate whether ascorbate levels in the tumour vary with markers of tissue hypoxia and epigenetic alterations.
The unique resource of the Tissue Bank will allow us to determine whether there is a relationship between ascorbate and the hypoxic pathway or epigenetic driver proteins, and whether there is any link with prognostic markers and with patient outcome. This will contribute important information for treating oncologists and their patients.
The main focus of Dr Phillips’ research is related to the field of cancer cell biology. Dr Phillips has mainly focused on breast cancer; investigating the mechanisms behind therapy resistance using proteomics and investigating the risk factor obesity and how it contributes to the progression of cancer.More About Dr Elisabeth Phillips